Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $102
Goldman Sachs analyst Madhu Kumar maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $91 to $102.
Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $113
Raymond James analyst Steven Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and raises the price target from $102 to $113.
Apellis Pharmaceuticals: Q2 Earnings Insights
Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Apellis Pharmaceuticals Q2 EPS $(1.46) Misses $(1.36) Estimate, Sales $16.32M Miss $16.94M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.36) by 7.35 percent. This is a 46.32 percent increase over losses of $(2.72) per
Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $86
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $81 to $86.
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:APLS) with a Buy rating and a $75 price target. The analyst expects Apellis’s…